Controversies in Schizophrenia Treatment
Introduction to Antipsychotic Drug Comparisons
The selection of the appropriate drug for treating schizophrenia continues to be a matter of debate, particularly due to the lack of comprehensive comparisons among various medications. A recent study aimed to compare antipsychotic drugs to identify the most effective treatment for individuals experiencing their first episode of schizophrenia, a crucial phase in the disorder.
Study Overview
A systematic review featuring pairwise and network meta-analyses was published in Lancet Psychiatry, focusing on the efficacy of antipsychotic treatments for first-episode schizophrenia. Researchers conducted extensive searches through databases such as MEDLINE, Embase, PsycINFO, Cochrane Library, PubMed, Biosis, and ClinicalTrials.gov for randomized controlled trials involving antipsychotic drugs used in acute treatment. The review included trials published up until 2016.
Research Methodology
The primary outcome assessed was the change in overall symptoms, while secondary outcomes encompassed differences in negative and positive symptoms, treatment response, dropout rates, treatment inefficacy, and side effects, including the management of parkinsonian symptoms, weight gain, sedation, prolactin levels, general functioning, and quality of life. A total of 19 randomized controlled trials were identified, involving 12 antipsychotic drugs and 2,669 participants.
Findings and Results
Although the quality of the data was relatively low, the results indicated that amisulpride, olanzapine, ziprasidone, and risperidone were more effective than haloperidol in reducing overall symptoms. Notably, olanzapine outperformed both haloperidol and risperidone in addressing negative symptoms. Additionally, many second-generation antipsychotics demonstrated a lower all-cause discontinuation rate compared to haloperidol. It was also noted that olanzapine required at least one other medication to manage parkinsonian symptoms. In terms of weight gain, molindone showed superiority over risperidone, haloperidol, and olanzapine, as well as a reduced prolactin release compared to risperidone.
Conclusion and Recommendations
Despite the necessity of this systematic review, the overall evidence quality was low, and the number of participants in each trial was limited. The authors concluded that haloperidol is an inferior choice for the acute treatment of first-episode schizophrenia. They also emphasized the minimal variation among second-generation antipsychotics in terms of treatment outcomes. Due to the absence of robust evidence, the review’s authors recommend that treatment decisions should primarily consider the side effects associated with each medication.
Reference
Zhu Y et al. (2017). Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Available: http://dx.doi.org/10.1016/S2215-0366(17)30270-5. Last accessed 28th Jul 2017.